Xenetic Biosciences, Inc. — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015. Xenetic is a clinical-stage biopharmaceutical company developing drug candidates and delivery platforms; it reported no commercial products or revenue. The filing was signed May 20, 2015.
Financial performance and position
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.04 million | $0.56 million; up 83% |
| General and administrative expense | $0.94 million | $2.39 million; down $1.46 million (61%) |
| Operating loss | $1.97 million | $2.96 million |
| Other expense | $0.46 million | $0.03 million |
| Net loss | $2.43 million | $4.06 million |
| Basic and diluted loss per share | $0.02 | $0.03 |
| Cash used in operating activities | $2.04 million | $4.12 million |
Gross profit and margins were not applicable because the company had no revenue or cost of revenue. The lower net loss versus Q1 2014 mainly reflected lower G&A costs and the absence of the prior-year $1.07 million loss on disposal of subsidiaries; the comparison was partly offset by higher R&D spending and foreign-exchange-related expense. Management attributed the $0.46 million of other expense primarily to currency movements, including the weakening of the British pound against the U.S. dollar.
At March 31, 2015, cash was $0.94 million, total current assets were $1.17 million, and current liabilities were $2.84 million, implying a working-capital deficit of approximately $1.67 million. The company reported total liabilities of $5.83 million and stockholders’ equity of $8.21 million. A $395,000 related-party loan was classified as current; it had matured and could be called due by agreement. A roughly $431,000 trade payable was disputed. The filing reports no off-balance-sheet financing arrangements.
Changes and operating developments
- R&D expense rose by $470,000, principally due to OncoHist IND-enabling preclinical work and higher outside-service and contract research costs. ErepoXen clinical-trial costs in Australia were approximately $360,000, versus $290,000 in Q1 2014.
- G&A fell by $1.46 million, reflecting lower legal, professional, accounting and tax costs after the UK-to-U.S. transition, reduced salaries, and the absence of approximately $345,000 in prior-year accelerated JSOP compensation.
- Operating cash outflow declined from $4.12 million to $2.04 million. Q1 2015 had no financing cash inflow; Q1 2014 included $10 million from Baxter’s share purchase and approximately $102,000 from option exercises.
- At March 31, the company had 149,985,476 common shares issued and 139,297,282 outstanding. On April 16, 2015, Chairman Mark Leuchtenberger resigned; the position was vacant when the filing was submitted.
Outlook, risks and contingencies
Management said it had received non-binding indications of interest for up to $3.2 million of additional working capital, net of expenses, and expected funding within approximately 10 business days after filing. It also said approximately $5 million more would be needed before the end of October 2015 to meet obligations through March 31, 2016; a further debt offering was contemplated for Q3 or Q4. These were not committed financings, and the filing gives no confirmation that they were completed.
Management estimated that the anticipated first financing would support the base business for about five months and said it planned to pursue a registered equity raise and national-exchange listing within 12 months. Failure to raise capital could require further reductions or suspension of preclinical work and externally conducted trials. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
Management did not expect significant collaboration receipts before 2016. Potential Baxter payments depend on clinical-development progress and milestones for its Factor VIII candidate; ErepoXen out-licensing was not expected to generate income before Q1 2016 at the earliest. Neither outcome was assured. The pipeline remained developmental: OncoHist had orphan-drug designations and planned U.S. IND-enabling work, while development of other candidates depended on funding and partner progress. The company also disclosed a $66,000 lease letter of credit and a related-party loan with uncertain repayment timing. No material legal proceedings were reported, and management reported disclosure controls effective at a reasonable-assurance level.
Important facts for investors to verify
- Whether the indicated financing of up to $3.2 million closed, on what terms, and whether the additional approximately $5 million was raised.
- Current cash, working capital, obligations and runway, including whether the related-party loan was called or the disputed payable resolved.
- Progress and funding requirements for OncoHist IND-enabling studies, ErepoXen trials and partner-led programs; confirm whether any clinical or collaboration milestones were achieved.
- Whether Baxter-related receipts or ErepoXen licensing income materialized, given the filing’s contingent timing assumptions.
- Any subsequent changes in the board, financing plans, or going-concern status after the filing date.